How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care

Journal of the American Dental Association

Volumn 141, Issue 5, 2010, Pages 562-566

  Migliorati, Cesar A ^a,b   Mattos, Katia ^c   Palazzolo, Mitzl J ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

Bisphosphonate; Dental care; Drugs; Medical care; Osteoporosis; Patient knowledge

Indexed keywords

EID: 77953427925     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2010.0229     Document Type: Article

References (25)

1. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22(10): 1479-1491.
2. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment (published correction appears in Lancet Oncol 2006; 7[7]: 533). Lancet Oncol 2006; 7(6): 508-514.
3. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws: 2009 update. J Oral Maxillofac Surg 2009; 67(5 suppl): 2-12.
4. Edwards BJ, Gounder M, McKoy JM, et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 2008; 9(12): 1166-1172.
5. Woo SB, Hellstein JW, Kalmar JR. Narrative (corrected) review: bisphosphonates and osteonecrosis of the jaws (published correction appears in Ann Intern Med 2006; 145[3]: 235). Ann Intern Med 2006; 144(10): 753-761.
6. Ciancio SG. Medications' impact on oral health. JADA 2004; 135(10): 1440-1448.
7. Gallagher L, Naidoo P. Prescription drugs and their effects on swallowing. Dysphagia 2009; 24(2): 159-166.
8. Nair K, Dolovich L, Cassels A, et al. What patients want to know about their medications; focus group study of patient and clinician perspectives. Can Fam Physician 2002; 48(1): 104-110.
9. Avorn J, Shrank WH. Communicating drug benefits and risks effectively: there must be a better way. Ann Intern Med 2009; 150(8): 563-564.
10. Delany N. How much do patients on lithium know about their medication? Psychiatr Bull 1991; 15(3): 136-137.
11. Polinski JM, Cadarette SM, Arnold M, et al. High-risk patients' readiness to undergo BMD testing for osteoporosis diagnosis in Pennsylvania. Int Q Community Health Educ 2008; 29(3): 223-240.
12. Gray CL, Gardner C. Adverse drug events in the elderly: an ongoing problem. J Manag Care Pharm 2009; 15(7): 568-571.
13. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005; 104(1): 83-93.
14. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61(9): 1115-1117.
15. Ruggiero SL, Mehrotra B, Rosenberg TJ, EngroffSL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62(5): 527-634. (Pubitemid 38542516)
16. Jadu F, Lee L, Pharoah M, Reece D, Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007; 18(12): 2015-2019. (Pubitemid 350286242)
17. Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007; 65(7): 1328-1331. (Pubitemid 46915477)
18. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper (published correction appears in JADA 2006; 137[1]: 26). JADA 2005; 136(12): 1658-1668.
19. Edwards BJ, Hellstein JW, Jacobsen PL, Kaltman S, Mariotti A, Migliorati CA; American Dental Association Council on Scientific Affairs Expert Panel on Bisphosphonate-Associated Osteonecrosis of the Jaw. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs (published correction appears in JADA 2009; 140[5]: 522). JADA 2008; 139(12): 1674-1677.
20. Keene GS, Parker MJ, Pryor GA. Mortality and morbidity after hip fractures. BMJ 1993; 307(6914): 1248-1250.
21. Leibson CL, Tosteson AN, Gabriel SE, Ransom JE, Melton LJ. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc 2002; 50(10): 1644-1650.
22. Robbins JA, Biggs ML, Cauley J. Adjusted mortality after hip fracture: from the cardiovascular health study. J Am Geriatr Soc 2006; 54(12): 1885-1891. (Pubitemid 44915832)
23. Nurit P, Bella BC, Gila E, Revital Z. Evaluation of a nursing intervention project to promote patient medication education. J Clin Nurs 2009; 18(17): 2530-2536.
24. Schwartz LM, Woloshin S, Welch HG. Using a drug facts box to communicate drug benefits and harms: two randomized trials. Ann Intern Med 2009; 150(8): 516-527.
25. Atlas SJ, Grant RW, Ferris TG, Chang Y, Barry MJ. Patientphysician connectedness and quality of primary care. Ann Intern Med 2009; 150(5): 325-335.